FTO and renal carcinoma: Although FTO inhibitors such as bisisantrene (Su et al., 2020), brequinar (Su et al., 2020), and Dac51 (Wu et al., 2023; Yang and Al-Hendy, 2023; Huang Y. et al., 2023; Liu Y. et al., 2021) have shown potency against several solid tumors, including renal carcinoma, bladder cancer, they may not be the ideal choice for the treatment of PCa model as researchers have confirmed the tumor suppressing role of FTO in PCa models.